Jump Start Stewardship Webinar 2: Building your Stewardship Team and Selecting Interventions and Targets for your Implementation Welcome Thank you for your time today This webinar will be recorded for your convenience A copy of today s presentation and the webinar recording will be available on the ABS Collaborative website and will a link will be emailed following the presentation This is intended to be an interactive discussion please ask questions and use the chat box throughout the presentation Agenda Review Identifying Stakeholders and Team Members Selecting Interventions and Targets for Implementation Next Steps and Homework Upcoming Educational Opportunities 1
Identifying Stakeholders and Team Members Identify Key Stakeholders for your ABS Plan Building your Stewardship Team and Resources o Tabs 5 9 in the workbook Stakeholder Identification 2
Resource Needs Assessment 3
Selecting Interventions and Targets for Implementation Selecting Interventions and Targets for Implementation Strategic Drivers of Stewardship o Leadership and Culture Change o Timely and Appropriate Initiation of Antimicrobial Therapy o Appropriate Administration and De-escalation of Therapy o Data Monitoring, Transparency, and Stewardship Key Factors to Consider when Selecting Interventions o Impact o Political Expediency o Resources Required o Ease of Implementation THE PROGRAM DOES NOT NEED TO BE IMPLEMENTED IN ITS FINAL VERSION Drivers of Optimal Antimicrobial Use Primary Driver Secondary Driver Key Change Concept Leadership and Culture Change Timely and Appropriate Initiation of Antibiotics Promote a culture of optimal antibiotic use within the facility Promptly identify patients who require antibiotics Obtain cultures prior to starting antibiotics Do not give antibiotics with overlapping activity or combinations not supported by evidence or guidelines Consider local antibiotic susceptibility patterns Specify expected duration of therapy based on evidence and national and hospital guidelines Engage administrative and clinical leadership to champion stewardship effort Develop a standardized process to identify patients who require antibiotics Create standardized protocols for ordering and obtaining cultures and other diagnostic tests prior to initiating antibiotics Develop a way to inform clinicians about unnecessary combinations of antibiotics, including double coverage Develop a standardized process for antibiotic selection Incorporate evidence-based guidelines for duration of antibiotics into standard protocols and/or computerized decision support 4
Primary Drivers Secondary Drivers Key ChangeConcepts Appropriate Administration and De-escalation of Therapy Data Monitoring, Transparency, and Stewardship Make antibiotics and start dates visible at point of care and electronic health records, as applicable Give antibiotics at the right dose and interval Stop or de-escalate therapy promptly based on the culture and sensitivity reports Reconcile and adjust antibiotics, at all transitions and changes in patient s condition Monitor, offer feedback, and make visible data regarding antibiotic utilization, antibiotic resistance, ADE, CDI, cost and adherence to prescribing practices Develop and make available expertise in antibiotic use Ensure expertise is available to clinicians at the point of care Ensure a clear history of patient antibiotic use is obtained and available Establish a process for delivery customized to the antibiotics and the patient 1. Established process for prompt notification of culture and antibiotic susceptibility results 2. Stop or de-escalate antibiotic based on culture results Look for all opportunities to stop or change antibiotic therapy when patient s condition changes and/or when changing levels of care Establish real-time monitoring and measurement systems 1. Cultivate local expertise among staff 2. Develop and process for antibiotic formulary management Create processes to ensure availability of expertise Assessment of ASP Interventions Intervention Advantages Disadvantages Notes Prospective audit with intervention and feedback Proven in clinical studies to reduce and modify use of antibiotics, improve selected clinical outcomes, and decrease antimicrobial expenditures (Joint Commission Resources, 2012) Resource intense Requires team member training and experience in antimicrobial therapy Voluntary adherence by clinicians to intervention Requires intervention for patients already on antimicrobials Requires ongoing review, intervention/feedback by and infectious disease physician or a clinical pharmacist with infectious disease training Formulary restriction and pre-authorization Proven in clinical studies to reduce and modify use of antibiotics, improve selected clinical outcomes, and decrease antimicrobial expenditures (Joint Commission Resources, 2012) When used with infection control interventions, effective in controlling C. difficile (Dellit, 2007) Potentially delays start of treatment Time intensive Perceived loss of prescriber autonomy (JCR, 2012) Requires on-call infectious disease physician or other trained professional to approve use Requires identifying specific antimicrobial agents to be restricted Can help control costs Requires monitoring overall trends in antimicrobial use to assess and respond to shifts in use (Dellit, 2007) Education Reaches a large number of prescribers in a short period of time (JCR, 2012) Effective for communicating the need and rationale for subsequent stewardship interventions (JCR, 2012; Dellit, 2007) Marginally effective in changing prescriber practices when used alone (Dellit, 2007) Has not demonstrated a sustained impact when used alone (Dellit, 2007) Rapid loss of knowledge when used alone (JCR, 2012) Can be incorporated into other meetings Can provide consistent messaging across the organization Assessment of ASP Interventions Intervention Advantages Disadvantages Notes Guidelines and Clinical Pathways Can improve antimicrobial utilization (Dellit, 2007) Reduces variation in prescribing practices (JCR, 2012) Evidence-based (Dellit, 2007) Assists with adherence to regulatory and third-party payer stipulations (JCR, 2012) Often not utilized unless combined with other stewardship strategies or elements (JCR, 2012) Acceptance by clinicians is better when local data are used and guideline is adapted to specific hospital (JCR, 2012) Streamlining or de-escalation of therapy More effectively targets the causative pathogen thereby reducing antimicrobial exposure Reduces costs associated with inappropriate treatment Can eliminate redundant combination therapy Requires culture results Requires monitoring use of initial, broad-spectrum empiric therapy for opportunities for more targeted treatment Parenteral to oral conversion ( IV to PO ) May allow for discontinuing venous access (improved patient comfort and mobility, decreased risk of phlebitis) (JCR, 2012) Cost savings (JCR, 2012; Dellit, 2007) Decreased length of stay (Dellit, 2007) Belief that IV therapy justifies continued hospitalization for third-party payers (myth) (JCR, 2012) May help facilitate discharges during surges in capacity (Dellit, 2007) Individual patient must be a good candidate for oral alternative (nutrition status, bio-availability of drug) 5
Feasibility of ASP Interventions Worksheet Making Your Interventions Specific Next Steps and Homework Complete tabs 1 through 13 in the workbook if you have not done so already o Take some time to consider what works for your organization o Be prepared to discuss some of the barriers that you encountered in section 3 during our next webinar Preview Section 4: Measuring Effectiveness Take advantage of other ABS Collaborative webinars 6
Upcoming Educational Opportunities Jump Start Stewardship Webinar #3 o June 13, 2017 1:00 2:00 pm o Registration: https://www.regonline.com/jumpstartstewardship3 Introducing and Initiating Pharmacy and Pharmacist Services with an ASP: Getting Pharmacists Involved in Leadership Roles o May 25, 2017, 1:00 2:00 pm o Register here Inpatient and Outpatient Webinar: Effective Data Tracking for ASP o By end of June o Registration forthcoming Outpatient Antibiotic Use and Stewardship o July 19, 9:00 10:00 am o Registration forthcoming ABS Collaborative Resources Resource links o MT ABS Collaborative Website: http://mpqhf.com/corporate/health-andtechnology-services/resources/abs-collaborative-resources/ Jumpstart Stewardship Toolkit Other toolkits and websites Leadership Commitment letter/statement templates and examples Other misc resources and links Contacts HIIN/STRIVE/Jump Start programs: MHA Casey Driscoll; casey.driscoll@mtha.org QIO- Mountain Pacific: Christy Fuller; cfuller@mpqhf.org; meichler@mpqhf.org DPHHS/Skaggs School of Pharmacy Vince Colucci; vince.colucci@mso.umt.edu Or email your FLEX, ICAR or other supporting member contact; gina.bruner@mtha.org pwebb@bresnan.net Not sure? Email Patty Kosednar, MT ABS Collaborative facilitator; pkosednar@mpqhf.org 7